HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.